ADC Therapeutics SA (ADCT) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SIGA Technologies (SIGA) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 58.9% versus a loss of 68.2%. Over five years, SIGA leads with a -71.9% price change compared with -94.2% for ADCT. ADC Therapeutics SA is the larger company by market cap ($180.0 million vs $172.5 million), about 1.0 times the size.
SIGA Technologies converts more of its revenue into profit, with a net margin of 24.6% versus -175.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | SIGA |
|---|---|---|
| Share price | $1.28 | $2.40 |
| Market cap | $180.05M | $172.45M |
| 1-day change | -1.54% | -9.43% |
| YTD return | -63.74% | -60.72% |
| 1-year return | -68.16% | -58.90% |
| 5-year return | -94.23% | -71.90% |
| P/E ratio (TTM) | — | 240.00 |
| Forward P/E | — | 5.45 |
| EPS (TTM) | $-0.46 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $81.36M | $94.57M |
| Revenue growth (YoY) | +14.85% | -31.82% |
| Net income (latest FY) | $-142.62M | $23.28M |
| Gross margin | 92.87% | 68.59% |
| Operating margin | -149.34% | 25.06% |
| Net margin | -175.31% | 24.61% |
| 52-week high | $4.98 | $7.11 |
| 52-week low | $0.78 | $2.30 |
| Distance from 52-week high | -74.30% | -66.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +160.16% | +35.42% |
| Average volume | 1.55M | 617.60K |
| Shares outstanding | 140.66M | 71.86M |
| Employees | 188 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SIGA Technologies is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -175.3 cents for ADC Therapeutics SA.
- ADC Therapeutics SA grew revenue faster in its latest fiscal year (+14.85% vs -31.82%).
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
ADCT vs SIGA FAQ
Which is bigger, ADC Therapeutics SA or SIGA Technologies?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $180.05M compared with $172.45M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, ADCT or SIGA?
SIGA returned -58.90% over the past 12 months, compared with -68.16% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.